{"id":"W4392718644","doi":"10.1016/j.eururo.2024.01.007","title":"Health-related Quality of Life in Patients with Previously Treated Advanced Urothelial Carcinoma from EV-301: A Phase 3 Trial of Enfortumab Vedotin Versus Chemotherapy","year":2024,"lang":"en","type":"article","venue":"European Urology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Astellas Pharma; Astellas Pharma US; Seagen; Pfizer","keywords":"Medicine; Discontinuation; Chemotherapy; Quality of life (healthcare); Internal medicine; Confidence interval; Chemotherapy regimen; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003477701,0.0002642637,0.0009479159,0.00017663,0.000023354,0.000005647713,0.0001263387,0.00008056444,0.0002378917],"category_scores_gemma":[0.0001320989,0.0002071841,0.0001388964,0.0003044871,0.000143024,0.00005642563,0.00002214025,0.0002516652,0.00002436501],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000103425,"about_ca_system_score_gemma":0.0004887959,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001715785,"about_ca_topic_score_gemma":0.00009549755,"domain_scores_codex":[0.9972325,0.0006327386,0.001055286,0.0004735697,0.0002760665,0.0003298373],"domain_scores_gemma":[0.9988158,0.0001845351,0.000333284,0.0004168708,0.0000796308,0.0001698409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8468177,0.003410459,0.09095459,0.0002077446,0.0008397463,0.0001097669,0.002912055,0.00001697528,0.0007071831,0.00005041587,0.000175634,0.05379771],"study_design_scores_gemma":[0.5844399,0.04115296,0.3721,0.000133989,0.0002275354,0.000002384672,0.00003269923,0.00004537497,0.0005621186,0.00002271577,0.001058234,0.0002220569],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939723,0.00130937,0.00002019785,0.0003772375,0.0004379988,0.001568319,0.000227157,0.00007700731,0.002010423],"genre_scores_gemma":[0.9990261,0.00006561576,0.00007273646,0.0002909085,0.0001074558,0.00002156567,0.0002489762,0.0000784172,0.00008828485],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2811454,"threshold_uncertainty_score":0.8448724,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02773329007438211,"score_gpt":0.3133052471279636,"score_spread":0.2855719570535815,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}